Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

Athersys to Host Year-End 2021 Financial Results Call

Business Wire February 15, 2022

Athersys to Host a Virtual Presentation on Its MultiStem® Programs

Business Wire January 26, 2022

Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer

Business Wire January 20, 2022

Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine

Business Wire November 30, 2021

Athersys Reports Third Quarter 2021 Results and Provides Corporate Update

Business Wire November 15, 2021

Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.

Business Wire November 12, 2021

Athersys to Host Third Quarter Financial Results Call

Business Wire October 18, 2021

Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference

Business Wire September 28, 2021

Biotech Stocks on Investors' Radar -- Athersys, AVEO Pharma, BioDelivery Sciences, and BioLine Rx

PR Newswire October 4, 2017

Athersys Reports Second Quarter 2017 Results

GlobeNewswire August 9, 2017

Investor Network: Athersys, Inc. to Host Earnings Call

Accesswire August 9, 2017

Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke

GlobeNewswire August 7, 2017

Stock Performance Review on Biotech Industry -- Athersys, AVEO Pharma, Heat Biologics, and Ignyta

PR Newswire July 13, 2017

Athersys to Host Second Quarter Financial Results Call

GlobeNewswire July 10, 2017

Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma

PR Newswire May 19, 2017

Athersys Reports First Quarter 2017 Results

GlobeNewswire May 9, 2017

Athersys to Host First Quarter Financial Results Call

GlobeNewswire April 10, 2017

Regenerative Technology Innovations in the Medical Market

PR Newswire April 4, 2017

Athersys to Present at Needham Healthcare Conference on April 4

GlobeNewswire March 29, 2017

22 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  March 29, 2017